Significant New Use Rules on Certain Chemical Substances (21-1.5e)
EPA proposes new use rules for certain chemicals, potentially affecting medical spa products like injectables and laser treatments. Requires notification before manufacturing or processing for significant new uses.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Medical spas and aesthetics clinics using chemical substances covered by the proposed SNURs, including injectables, laser products, and other aesthetic treatments. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments on the proposed rule are due by August 10, 2021. Compliance with the final rule will be required 90 days after publication of the final rule.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
EPA proposes that any person manufacturing or processing the listed chemical substances for a significant new use must notify EPA at least 90 days before starting that activity.
Who it affects
Medical spas and aesthetics clinics using chemical substances covered by the proposed SNURs, including injectables, laser products, and other aesthetic treatments.
What you must do
Review the list of chemical substances in the proposed rule to determine if any products used in your clinic are affected. If so, submit a significant new use notice (SNUN) to EPA before using them for the new use.
Deadline
Comments on the proposed rule are due by August 10, 2021. Compliance with the final rule will be required 90 days after publication of the final rule.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication